The First Russian Strategic Study of Pharmacotherapy for Rheumatoid Arthritis (Remarca Trial): Results of 12-Month Treatment in 130 Patients

Karateev, D. E.; Лучихина, Е. Л.; Демидова, Н. В.; Gridneva, G. S.; Kanonirova, M.; Muravyev, Yu. V.; Lukina, G.; Olyunin, Yu A; Касумова, К. А.; Александрова, Е. Н.; Novikov, A.; Avdeeva, A. A.; Popkova, T.; Новикова, Д. С.; Смирнов, А. В.; Волков, А. В.; Насонов, Е. Л.

doi:10.14412/1995-4484-2016-63-70

rsp

2016

DOI: 10.14412/1995-4484-2016-63-70

|View full text |Cite

The First Russian Strategic Study of Pharmacotherapy for Rheumatoid Arthritis (Remarca Trial): Results of 12-Month Treatment in 130 Patients

D. E. Karateev¹,

Е. Л. Лучихина²,

Н. В. Демидова³

et al.

Abstract: О р и г и н а л ь н ы е и с с л е д о в а н и я ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2017

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specificity of the Russian T2T study was the predominant use of subcutaneous MTX in high concentration and its fast dose increase, the absence of glucocorticoid, early involvement of biological therapy, and stringent remission criteria. 17 Subcutaneous MTX delivery demonstrated higher efficacy and better tolerance compared to pills. 18 Since then, 76% of patients included in REMARCA study reside in Central Russia.…”

mentioning

confidence: 99%

“…14 Starting in 2011, it was transformed into the OREL registry, which quickly developed as an internet-based project and now includes 3,276 RA patients. 17 The OREL registry contains the most comprehensive data about RA patients in Russia. 14 The registry demonstrates a significant prevalence of RA in city residents over rural, although this may also be associated with the concentration of rheumatologic care centers in big cities, and their limited availability in the villages.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Current and future trends in Russian Rheumatology Care and Research

Tchetina¹

2017

MJR

View full text Add to dashboard Cite

This short article provides a description of the present state of rheumatology care and research in Russia and discusses opportunities for development and cooperation. Rheumatic diseases (RDs) in Russia represent the second most common pathology after cardiovascular disorders. Although RDs include more than 200 diseases and syndromes, the most common in Russia are osteoarthritis (OA), rheumatoid arthritis (RA), gout, and low back pain, largely similar to those seen in most Western societies. Interestingly, the prevalence of RA appears to have increased from 0.42% to 1% in the Russian population since the last large-scale epidemiologic study, which was conducted 25 years ago in the former USSR; this is an opposite trend to that seen in most Western countries 1 and is similar to other reports that have indicated that RA prevalence has risen in Europe and North America due to the underlying aging population 2 and increasing patient survival. 3 This would be interesting to study in comparative collaborative research. Approximately 10% of the Russian population is presently affected by RDs. 4 The major factors responsible for the increased prevalence of RDs in Russia include increased mutation activity associated with environmental pollution and an augmented incidence of concomitant disorders such as obesity, diabetes mellitus, hypertension, and others. Recent large epidemiologic study including 76,000 subjects from 18 regions of the Russian Federation revealed that statistical indices are significantly lower (up to 5-fold) than real prevalence of RDs among adults registered according to the attendance in clinics. 5 Besides, individual federal regions demonstrate different dynamics. For example, in Central Russia, the incidence of almost all RDs excluding osteoporosis decreased, while in the Western region, an increase in the incidence of RA and OA during one year of follow-up was observed. 6 Russia is a large territory and has a multinational population. This provides the opportunity to study different disease subtypes and phenotypes associated with genetic variability, national psychological traits, various climates, ecological conditions, and environmental factors. However, all these possibilities are limited by the insufficient funding of rheumatic research. Therefore, such type of research is a subject for future studies. Recently, Russia is developing a three-level standardized system for management of RD patients involving primary medical care, specialized treatment protocols, and rehabilitation technologies developed by the leading rheumatologic centers. Russia has great tradition in rehabilitation. Recent studies on combination of "treat to target" therapies with concomitant rehabilitation program have demonstrated that this approach is more efficient than pharmacological therapy alone primarily for early RA patients. It involves

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Current and future trends in Russian Rheumatology Care and Research

Tchetina¹

2017

MJR

View full text Add to dashboard Cite

show abstract

Use of Subcutaneous Methotrexate for the Treatment of Patients With Active Rheumatoid Arthritis: The Remarca Trial

Каратеев¹,

Лучихина²,

Демидова³

et al. 2016

rsp

Self Cite

View full text Add to dashboard Cite

О р и г и н а л ь н ы е и с с л е д о в а н и я За последние 20 лет применение метотрексата (МТ) стало «золотым стандартом» лечения ревматоидного артрита (РА) [1-3]. Российские [4] и международные [5, 6] клинические рекомендации подтверждают эту позицию на основании обширных клинических данных с высоким уровнем доказательности. Раннее назначение МТ, использование высоких (по стандартам ревматологической практики) доз препарата способствуют повышению эффективности терапии [7, 8] и уменьшению «тяжести» РА на популяционном уровне [9-12]. Одним из важных достоинств МТ при лечении РА является возможность подбора дозы и путей введения (перорально или подкож-1 ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой,

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The First Russian Strategic Study of Pharmacotherapy for Rheumatoid Arthritis (Remarca Trial): Results of 12-Month Treatment in 130 Patients

Abstract: О р и г и н а л ь н ы е и с с л е д о в а н и я ФГБНУ Научноисследовательский институт ревматологии им. В.А. Насоновой,

Cited by 2 publications

References 7 publications

Current and future trends in Russian Rheumatology Care and Research

Current and future trends in Russian Rheumatology Care and Research

Use of Subcutaneous Methotrexate for the Treatment of Patients With Active Rheumatoid Arthritis: The Remarca Trial

Contact Info

Product

Resources

About